Stephens Investment Management Group LLC Raises Holdings in DexCom, Inc. $DXCM

Stephens Investment Management Group LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.0% in the 1st quarter, Holdings Channel reports. The fund owned 1,074,465 shares of the medical device company’s stock after buying an additional 31,664 shares during the quarter. Stephens Investment Management Group LLC’s holdings in DexCom were worth $67,476,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the company. Reflection Asset Management bought a new stake in DexCom in the 4th quarter valued at about $25,000. CVA Family Office LLC boosted its position in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. MCF Advisors LLC purchased a new position in shares of DexCom in the fourth quarter worth about $32,000. ORG Partners LLC increased its stake in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares in the last quarter. Finally, DV Equities LLC bought a new stake in shares of DexCom in the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Mizuho set a $85.00 price target on shares of DexCom and gave the company an “outperform” rating in a research note on Tuesday, June 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a research note on Monday, June 1st. UBS Group set a $95.00 target price on shares of DexCom in a report on Wednesday, June 10th. BTIG Research restated a “buy” rating and set a $85.00 target price on shares of DexCom in a research report on Monday, March 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $88.00 price target (up from $75.00) on shares of DexCom in a report on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $84.88.

DexCom Stock Performance

Shares of DexCom stock opened at $71.25 on Friday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The company has a market cap of $27.49 billion, a price-to-earnings ratio of 30.45, a PEG ratio of 1.17 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company’s 50-day moving average price is $68.31 and its 200-day moving average price is $68.17.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.32 earnings per share. On average, equities analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. This represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the sale, the director owned 52,852 shares in the company, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 46,694 shares of company stock worth $3,343,977. Company insiders own 0.28% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.